Campylandra fimbriata

Campylandra fimbriata: A Comprehensive Reference Article

1. Identity: Botanical Classification, Nomenclature, and Synonymy

Campylandra fimbriata is a perennial rhizomatous herb belonging to the family Asparagaceae (order Asparagales, class Equisetopsida, subclass Magnoliidae, phylum Streptophyta, kingdom Plantae). Its full taxonomic placement situates it within the order Asparagales, family Asparagaceae, genus Campylandra.

Accepted name (Flora of China): Campylandra fimbriata (Hand.-Mazz.) M.N.Tamura, S.Yun Liang & Turland — formally published in Novon 10: 159 (2000).

The species has accumulated a substantial synonymy across more than a century of taxonomic revision:

• Tupistra fimbriata Handel-Mazzetti — the basionym, originally described in 1922
• Rohdea fimbriata (Hand.-Mazz.) Yamashita & M.N.Tamura — a later recombination
• Rohdea delavayi (Franch.) N.Tanaka — under which some checklists now treat the taxon
• Campylandra delavayi — an intermediate recombination used in certain references
• Rohdea lihengiana Q.Qiao & C.Q.Zhang — described separately but later merged
• Tupistra fimbriata var. breviloba H.Li & J.L.Huang — an infraspecific variety no longer maintained

The formal combination Campylandra fimbriata (Handel-Mazzetti) M.N.Tamura, S.Yun Liang & Turland was published in 2000, based on the basionym Tupistra fimbriata Handel-Mazzetti, which Handel-Mazzetti described from specimens collected in Yunnan, China — specifically "in pluviisilva frondosa calide temperata juxta vicum Bahan in convalle fluvii Salween, 27°58′N," at approximately 2,600 m elevation, on 20 June 1916 (Handel-Mazzetti 8804, holotype at W).

The Plant List records this name as a synonym of Rohdea delavayi (Franch.) N.Tanaka, reflecting ongoing disagreement among authorities as to the correct placement. Juniper Level Botanic Garden's Rohdea reference confirms that Rohdea delavayi (also called Tupistra/Campylandra delavayi and Tupistra/Campylandra fimbriata) is distributed across six Chinese provinces.

The Chinese common name recorded for the broader genus in Flora of China is 开口箭属 (kāi kǒu jiàn shǔ), meaning "open-arrow genus." In Simplified Chinese, the species carries the specific epithet name 齿瓣开口箭 (chǐ bàn kāi kǒu jiàn), as recorded in the Flora Reipublicae Popularis Sinicae, volume 15.

1.1 Genus-Level Taxonomy and Morphological Distinctions

The genus Campylandra is placed in the family Asparagaceae among the angiosperms (flowering plants). The distinction of Campylandra from the closely allied genus Tupistra has been debated for over a century, with various authors either uniting or separating the two. Subsequently, various authors have either united Campylandra with Tupistra Ker Gawler (sometimes recognizing it as a subgenus or section of Tupistra) or maintained it as a separate genus. The present authors regard Campylandra as separate on account of its having filaments only proximally (vs. almost wholly in Tupistra) adnate to the perianth tube, anthers as high as or higher (vs. lower) than the stigma, a shorter style, and a 3-lobed (vs. peltate to mushroom-shaped) stigma; this separation is confirmed by molecular phylogenies.

The forthcoming Flora of China, Volume 24, treats Campylandra and Tupistra as separate genera, distinguishing them as follows: Campylandra has filaments proximally adnate to the perianth tube, anthers positioned as high as or higher than the stigma, and a style usually 0–1 mm (rarely to 3.5 mm in C. fimbriata), with a small 3-lobed stigma; whereas Tupistra has filaments almost wholly adnate to the perianth tube, anthers lower than the stigma, and a style 4–12 mm with a peltate to fungilliform, 2–7 mm fleshy stigma.

According to karyological and palynological data, Campylandra has unimodal karyotypes, and ellipsoid or subspherical, monosulcate pollen grains with reticulate or perforate exine, whereas Tupistra has bimodal karyotypes (except in T. nutans: unimodal), and spherical, inaperturate pollen grains with rugulose, verrucose, or gemmate exine.

When the genus Campylandra was formally revised in 2000, twelve species previously treated under Tupistra were transferred to Campylandra, among them T. fimbriata Handel-Mazzetti, reflecting the molecular phylogenetic confirmation that the two genera are distinct.

2. Geographic Distribution and Natural Habitat

Campylandra fimbriata is native to southwestern China. Its type locality is in Yunnan Province, specifically in the valley of the Salween River (Nu Jiang) at approximately 2,600 m elevation — a broadleaved, warm-temperate rain forest environment. The broader taxon to which it belongs (Rohdea delavayi, which encompasses Campylandra fimbriata and related nomenclatural synonyms) is recorded from six Chinese provinces.

The genus as a whole is characteristic of the forest understory in subtropical and warm-temperate montane zones of Asia. The genus Tupistra (family Asparagaceae) is a genus of flowering plants that can be found in Asia. Members of Campylandra and closely related genera favour shaded, humid forest floors, typically growing as rhizomatous ground herbs in mixed or evergreen broadleaved forests at moderate to high elevations. The Yunnan–Sichuan region of southwestern China, where the species is native, is among the world's most botanically diverse temperate regions, providing a habitat of dense canopy shade, rich organic soils, and seasonal monsoon rainfall.

3. Botanical Description

Campylandra fimbriata is a perennial evergreen herb with a creeping or ascending rhizome. Like other members of its genus and the closely allied genus Tupistra, it produces strap-shaped or lanceolate basal leaves arranged in a rosette pattern. The inflorescence, characteristic of the genus, is a spike-like or racemose structure borne on a short peduncle arising from the rhizome, bearing small tubular perianth flowers. The fruit is a berry. In C. fimbriata specifically, the style is unusually long relative to other members of Campylandra, with the style reaching rarely up to 3.5 mm, which is notably longer than in most other Campylandra species where the style is usually 0–1 mm.

The species epithet fimbriata (Latin: "fringed") refers to a fringed or lacerate margin on the perianth lobes — a distinguishing morphological character captured in its Chinese common name 齿瓣开口箭, meaning "toothed-petal open-arrow."

4. Traditional and Historical Use

4.1 Use in Chinese Traditional Medicine

Campylandra fimbriata belongs to the genus-level folk medicine complex known in Chinese as 开口箭 (kāi kǒu jiàn, "open-mouth arrow" or "open-arrow"), a name applied across multiple closely related Campylandra/Tupistra species whose rhizomes have been used interchangeably in regional folk practice. The species of this genus possess similar morphological characteristics, and some can be substituted for each other as folk medicine to treat pharyngolaryngitis, rheumatic diseases, and snake-bite. The dried rhizome of closely related species is a famous folk medicine for the treatment of carbuncles and pharyngitis.

The roots and rhizomes of these plants are commonly used as folk medicine to treat throat irritation, rheumatic diseases, and snake-bites. In Chinese traditional medicine, the rhizome preparation — typically dried — has been used to address swellings, carbuncles, and inflammatory conditions of the throat and airways, as well as musculoskeletal complaints associated with rheumatic disease.

The earliest dedicated pharmacological study of Tupistra fimbriata (the former name of C. fimbriata) appeared in the Chinese-language scientific literature in the early 1960s. A pharmacological study of Tupistra fimbriata H-M. examining specifically its cardiotonic effect, cumulative effect, speed of onset of action, and therapeutic coefficient was published by Yeau KL and Chou YS in Yao Xue Xue Bao (Acta Pharmaceutica Sinica), 10: 745–50, in December 1963 (PMID 14098718). This study placed T. fimbriata within a broader research programme investigating native Chinese plants with potential cardiac glycoside-type activity — a tradition grounded in the known cardioactive properties of several related genera.

4.2 Contextual Folk Use Within the Genus

Folk medicinal use of Campylandra/Tupistra plants in China encompasses treatments for several clinical presentations. The closely related species Tupistra chinensis Baker (syn. Rohdea chinensis), an antitumor folk herb mainly distributed in China, has its rhizome historically used to treat gastric cancer. In the context of regional ethnomedicine, particularly across the Qinba Mountains of Shaanxi Province and the Yunnan–Sichuan corridor, various kai kou jian species have been prepared as decoctions or poultices for pharyngeal inflammation and as antidotes to snake venom.

The traditional use of these plants in cardiac conditions is particularly notable. The early Chinese pharmacological literature investigated the cardiotonic potential of T. fimbriata specifically because indigenous practitioners in relevant regions had noted its effects on the heart and circulation — a use consistent with the later phytochemical discovery of cardenolide-type compounds (steroidal cardiac glycoside aglycones) in the genus.

5. Key Constituents and Active Compounds

5.1 Genus-Level Phytochemical Profile

The phytochemistry of Campylandra fimbriata has not been investigated in isolation to the same degree as the closely related and taxonomically overlapping Tupistra chinensis or T. yunnanensis. However, given the extent of synonymy, the shared geographic range, and the genus-level chemical consistency documented in the scientific literature, the phytochemical profile of the Campylandra/Tupistra group provides the closest verified approximation. A comprehensive 2022 review of the genus Tupistra in Natural Product Communications synthesised the available phytochemical data across the genus. In that review, secondary metabolites separated from Tupistra plants were compiled; approximately 200 phytochemicals, classified in various chemical classes of bioactive compounds, were identified. The most striking feature is that the most frequently isolated compounds are spirostanol sapogenins, and spirostanol and furostanol saponins, most of which are new in nature.

Additional compound classes identified from the genus include alkaloids, lignans, amides, and triterpenoids.

5.2 Steroidal Saponins (Spirostanol and Furostanol Types)

Steroidal saponins constitute the dominant and most pharmacologically relevant class of secondary metabolites in this genus. Previous phytochemical investigations on the closely related T. chinensis have led to the isolation of a variety of biologically active compounds, including steroidal sapogenins and their glycosides, cardenolides, a pregnane genin and its glycoside, and flavonoids, which have anti-inflammatory, cytotoxic, and antifungal activities.

Structurally, these saponins fall into two principal skeletal types:

• Spirostanol saponins — characterised by a closed furan ring at C-22 with sugar chains typically attached at C-3; these represent the most frequently encountered class in the genus.
• Furostanol saponins — characterised by an open furanose ring at C-22 with sugar chains at both C-3 and C-26 positions.

In detailed phytochemical work on Tupistra chinensis, nine novel spirostanol saponins were characterised, including structures such as spirost-25(27)-en-1β,2β,3β,4β,5β-pentol-2-O-β-D-xylopyranoside and spirost-25(27)-en-1β,3α,5β-triol, among many related polyhydroxylated compounds.

Specific furostanol saponins identified from the roots and rhizomes of this genus include 1β,2β,3β,4β,5β,26-hexahydroxyfurost-20(22),25(27)-dien-5,26-O-β-d-glucopyranoside and 1β,2β,3β,4β,5β,6β,7α,23ξ,26-nonahydroxyfurost-20(22),25(27)-dien-26-O-β-d-glucopyranoside, along with known compounds such as tupisteroide B.

Steroidal saponins are prominent bioactive constituents present in monocot plants, primarily comprising sugars and glycosides. They significantly contribute to natural product chemistry due to their profound pharmacological attributes and demonstrated efficacy in treating a plethora of diseases.

5.3 Cardenolides

Cardenolides — steroidal cardiac glycoside aglycones and their glycosides — have been documented as a secondary chemical class within the genus. Modern pharmacological experiments have shown that extracts of these species possess significant antitumor activities, and two main kinds of components — cardenolides and saponins — were isolated from closely related Tupistra species. The presence of cardenolide-type structures provides a phytochemical rationale for the traditional use of these plants in cardiac conditions, and for the early 1963 pharmacological investigation of the cardiotonic effect of T. fimbriata specifically.

5.4 Flavonoids

Flavonoids, including flavans and flavanone-type compounds, have also been isolated from members of this genus. These represent a secondary but bioactive class of constituents, with documented contributions to anti-inflammatory and antioxidant properties observed in vitro for the genus.

5.5 Other Secondary Metabolites

Based on genus-level investigations, additional compound classes present in Campylandra/Tupistra species include pregnane genins and their glycosides (pregnane glycosides), phenolic acids, and aromatic derivatives. Regarding phytochemical reports, steroids, flavonoids, phenols, and aromatic derivatives can be considered the major chemical classes from this genus.

6. Mechanisms of Action

6.1 Anti-Inflammatory Mechanisms

Steroidal glycosides as important secondary metabolites of medicinal plants have been reported to possess a wide range of biological activities including anticancer, anti-inflammatory, platelet aggregation inhibition, antihypertensive, cholesterol-lowering, antifungal, and antiviral properties. For the spirostanol saponins specific to this genus, inhibition of nitric oxide (NO) production in macrophage-like cell systems has been demonstrated, indicating suppression of inducible nitric oxide synthase (iNOS) as one mechanistic pathway. Compounds from related Tupistra species showed significant inhibition of NO production with IC₅₀ values of 11.5 μM.

6.2 Anticancer/Cytotoxic Mechanisms

In vivo cancer-related activities of tested Tupistra samples were mostly based on apoptosis. For the closely related T. chinensis — whose steroidal saponins are structurally analogous to those expected in C. fimbriata — the pro-apoptotic mechanisms documented include:

• PI3K/Akt/mTOR pathway inhibition: Total steroidal saponins of T. chinensis effectively induced apoptosis by the PI3K/Akt/mTOR signalling pathway in SGC-7901 (gastric cancer) cells.
• p53-mediated apoptosis: In AGS gastric cancer cells, apoptosis was promoted via a p53-mediated pathway.
• Cell migration inhibition: Total steroidal saponins also exhibited inhibitory activity in blocking the migration of gastric cancer cells, and in vivo significantly inhibited the growth of xenograft tumours.

6.3 Cardiotonic Mechanisms

The cardiotonic activity investigated for Tupistra fimbriata (now Campylandra fimbriata) in the 1963 pharmacological study is consistent with cardenolide-type mechanisms. Cardiac glycosides and cardenolides classically inhibit the Na⁺/K⁺-ATPase pump on cardiomyocytes, increasing intracellular sodium and indirectly increasing calcium, thereby enhancing cardiac contractility (positive inotropy). The 1963 study examined the cardiotonic effect, cumulative effect (i.e., tendency for pharmacological accumulation), speed of onset, and therapeutic coefficient — parameters standard in the evaluation of digitalis-type compounds. No English-language abstract is available for this study (published in Chinese), and therefore no specific numerical findings from it can be verified and cited.

7. Scientific Evidence by Area of Use

7.1 Cardiotonic / Cardiovascular Activity

Evidence level: Historical animal/ex vivo study only; no modern clinical data.

The single indexed pharmacological study specific to Campylandra fimbriata (as Tupistra fimbriata) dates to 1963 and was published in Chinese. The pharmacological study of Tupistra fimbriata H-M. Part II, examining the cardiotonic effect, cumulative effect, speed of onset of action, and therapeutic coefficient, was published by Yeau KL and Chou YS in Yao Xue Xue Bao, 10: 745–50, December 1963. No English abstract is available, and no subsequent modern replication in a peer-reviewed English-language journal with human participants has been identified in available sources. This study is therefore considered preliminary preclinical evidence of significant historical interest, but it cannot be used to establish clinical efficacy.

7.2 Anti-inflammatory Activity

Evidence level: Preclinical (cell-based and animal); no human clinical trials identified.

Anti-inflammatory activity has been extensively documented for the genus as a whole, primarily through in vitro and animal studies on the most-studied species T. chinensis. Tupistra constituents have demonstrated valuable properties in the field of pharmacology, such as antioxidative, antimicrobial, antidiabetic, and antihepatic activities, but their cytotoxic and anti-inflammatory actions can be considered the more remarkable. The mechanism, as established in laboratory models, involves inhibition of NO production and related pro-inflammatory signalling cascades in macrophage cell lines. No human clinical trial of an extract of C. fimbriata for any inflammatory condition has been identified in the available literature. Evidence is therefore exclusively preclinical.

7.3 Anticancer/Cytotoxic Activity

Evidence level: Preclinical (in vitro cell lines, some in vivo rodent xenograft models); no human clinical trials identified.

The most extensively studied area of pharmacological activity for the genus is cytotoxicity against cancer cell lines. For the closely related T. chinensis, whose steroidal saponin chemistry is the most detailed in the literature:

• In vitro, total steroidal saponins (TCS) of T. chinensis inhibited the proliferation of gastric cancer cells; in vivo, TCS significantly inhibited the growth of xenograft tumours; these results indicated that TCS exhibited significant anti-gastric cancer effects in vitro and in vivo. This represents animal and cell-line evidence only.
• In vitro cytotoxic activity of specific spirostanol saponins was evaluated on human A549 and H1299 tumour cell lines; compound 3 (a novel spirostanol saponin) exhibited cytotoxicity against A549 cells (IC₅₀ 86.63 ± 2.33 μmol·L⁻¹) and H1299 cells (IC₅₀ 88.21 ± 1.34 μmol·L⁻¹).
• Spirostanol saponins isolated from the dried rhizomes of T. chinensis have potent antiproliferative and anti-inflammatory activities.

All anticancer findings are preclinical. No clinical trial evidence of anticancer activity attributable to Campylandra fimbriata itself is available in the indexed literature.

7.4 Antimicrobial Activity

Evidence level: Preliminary preclinical; no human data.

Tupistra constituents have demonstrated antioxidative, antimicrobial, antidiabetic, and antihepatic activities across genus-level investigations. Antimicrobial and antifungal activities have been attributed specifically to the steroidal saponin fraction. Previous phytochemical investigations have identified compounds with antifungal activities in related species. Evidence at this stage is restricted to in vitro assays with no clinical corroboration.

7.5 Antioxidant Activity

Evidence level: In vitro only; no human data.

Antioxidant properties have been noted for genus members across several laboratory-based assays, attributable to the flavonoid and phenolic acid fractions. Antioxidative activity is among the valuable properties demonstrated by Tupistra constituents in the field of pharmacology. No controlled human trial data exists.

7.6 Antidiabetic Activity

Evidence level: Preliminary preclinical; no human data.

Antidiabetic activity has been demonstrated for Tupistra genus constituents in pharmacological investigations. However, no study specific to C. fimbriata and no human clinical study of any closely related species for glycaemic management has been identified in the current literature search.

8. Body Systems Associated with This Plant

• Cardiovascular system: Cardiotonic activity documented in a 1963 pharmacological study (preclinical, historical).
• Immune and inflammatory system: Inhibition of NO production and pro-inflammatory mediators in cell-based models; traditionally used for carbuncles, pharyngitis, and inflammatory swellings.
• Oncology-related (experimental): Cytotoxic and antiproliferative activity against multiple cancer cell lines documented for the genus in vitro and in xenograft models.
• Musculoskeletal system: Traditional use for rheumatic diseases across Campylandra/Tupistra folk medicine applications.
• Gastrointestinal system: Related species used traditionally for gastric complaints; polysaccharides from the genus have been examined for effects on gut microbiota.
• Respiratory/ENT system: Traditional use in pharyngitis, pharyngolaryngitis, and throat irritation.
• Toxicology (snake envenomation): Traditional use as a folk antidote for snake-bite, documented for the genus.

9. Dosage Forms and Preparations

Campylandra fimbriata is used primarily in its rhizome form. Traditional preparations documented for the broader kai kou jian complex include:

• Dried rhizome decoction: The most common traditional preparation, used internally for pharyngitis, rheumatic disease, and snake-bite, as documented across Chinese regional ethnobotany.
• Fresh rhizome poultice: Applied externally for carbuncles and skin swellings in traditional practice.
• Alcoholic extract (ethanol or methanol): Used in scientific research to prepare standardised extracts for pharmacological studies; referenced in the phytochemical literature for genus members such as T. chinensis (e.g., 60% ethanol rhizome extracts).
• Total steroidal saponin (TSS) fraction: An isolated and partially purified research preparation used in the major preclinical studies on anticancer activity.

No standardised dosage for human use has been established or reported in any clinical study for C. fimbriata specifically. The 1963 pharmacological study on the cardiotonic effect (PMID 14098718) does not have an available English-language abstract from which dose parameters can be verified. All dosage information in the preclinical literature relates to in vitro concentration ranges (e.g., IC₅₀ values in μM for isolated compounds in cell assays) or xenograft tumour models, and cannot be directly extrapolated to human dosing.

10. Safety Considerations

10.1 Toxicological Profile

No dedicated human safety or toxicology study of Campylandra fimbriata has been identified in the indexed biomedical literature. Safety data are therefore entirely absent for human exposures. Given the presence of cardenolide-type compounds documented for closely related genera and species, there is a well-grounded theoretical basis for cardiac toxicity risk: cardenolides act on Na⁺/K⁺-ATPase and at sufficient doses can cause arrhythmias, nausea, vomiting, and cardiac arrest — properties shared by the digitalis glycoside class. The 1963 pharmacological investigation of T. fimbriata specifically examined the "cumulative effect" and "therapeutic coefficient" — both parameters of direct relevance to assessing cardiac glycoside toxicity and the margin between therapeutic and lethal doses. Investigation of these parameters implies that the researchers recognised a narrow therapeutic window consistent with cardenolide pharmacology.

10.2 Potential Drug Interactions

No interaction studies involving Campylandra fimbriata and pharmaceutical drugs have been identified in the literature. Based on the compound classes present (cardenolides, saponins), theoretical interaction concerns include:

• Digoxin and cardiac glycoside medicines: Additive or synergistic cardiotonic effects are theoretically possible given the cardenolide content.
• Anti-arrhythmic drugs: Plants containing cardenolide-type compounds may interfere with heart rate and rhythm-modifying medications.

These are theoretical inferences from compound-class pharmacology and have not been studied or documented in clinical or pharmacokinetic investigations specific to this species.

10.3 Availability and Regulatory Status

Campylandra fimbriata is not listed in any major Western pharmacopoeia (European Pharmacopoeia, USP, or British Pharmacopoeia). It does not appear in any WHO monograph, ESCOP monograph, or German Commission E positive or negative monograph. It is not assessed by the NIH Office of Dietary Supplements, NCCIH, EFSA, or EMA in any public document identified by the current literature search. It therefore operates entirely outside the framework of evidence-based regulatory recognition in Western markets.

11. Current State of Research and Limitations

Further phytochemical investigations, together with extensive assessments of the biological profiles and mechanism of action studies of the components of Tupistra/Campylandra species, are to be expected. The following critical limitations define the current evidence base:

• Species-specific data are sparse. Virtually all modern pharmacological work references Tupistra chinensis or the genus broadly, not Campylandra fimbriata itself. Extrapolating genus-level findings to this species is scientifically plausible but unconfirmed.
• No human clinical trials exist. Every area of pharmacological activity reviewed above — cardiotonic, anti-inflammatory, anticancer, antimicrobial, antidiabetic — is supported exclusively by in vitro or animal evidence.
• No standardised preparation exists. There is no defined, validated extract, dosage form, or quality standard for C. fimbriata in any regulatory system.
• Taxonomic instability complicates attribution. The species has been transferred between Tupistra, Campylandra, and Rohdea, and some authorities treat it as a synonym of Rohdea delavayi. This makes cross-referencing older literature with modern phytochemical work challenging.
• Safety data are absent. No formal toxicological or safety study of this species in humans has been published in any indexed source.

References

• Plants of the World Online — Campylandra fimbriata (Hand.-Mazz.) M.N.Tamura, S.Yun Liang & Turland (Kew Science)
• The Plant List — Campylandra fimbriata (Hand.-Mazz.) M.N.Tamura, S.Yun Liang & Turland
• Plants of the World Online — Rohdea delavayi (Franch.) N.Tanaka (Kew Science)
• Tamura MN, Liang SY, Turland NJ — New Combinations in Campylandra (Convallariaceae-Convallarieae), Novon 10: 159 (2000) — Harvard University Herbaria
• Wikidata — Tupistra fimbriata (taxon record with cross-references to Flora Reipublicae Popularis Sinicae)
• PubMed — Yeau KL, Chou YS. The pharmacological study of Tupistra fimbriata H-M. II. Cardiotonic effect, cumulative effect, speed of onset of action, and therapeutic coefficient. Yao Xue Xue Bao 1963;10:745–50. PMID 14098718
• Linh NTT, Ha NM, Son NT. Genus Tupistra: A Comprehensive Review of Phytochemistry and Pharmacological Activity. Natural Product Communications 2022. SAGE Publications.
• Xiang L, Yi X, Wang Y, He X. Antiproliferative and anti-inflammatory polyhydroxylated spirostanol saponins from Tupistra chinensis. Scientific Reports 2016;6:31633. PMC4987684.
• Steroidal Saponins from the Roots and Rhizomes of Tupistra chinensis. Molecules 2019. PMC6332035.
• Total saponins from Tupistra chinensis Baker inhibits growth of human gastric cancer cells in vitro and in vivo. PubMed PMID 34116191.
• Flora of China @ eFloras.org — Genus Campylandra (开口箭属 kai kou jian shu)
• New species of the genus Campylandra (Convallariaceae-Convallarieae) from Thailand — ResearchGate
• Steroidal saponins: a treasure trove of natural resources that require urgent development. Phytochemistry Reviews, Springer Nature, 2025.